1800 202 8726
Soft tissue IHC markers explained

Vimentin, Desmin and — What Soft Tissue Markers Mean

A sarcoma biopsy report can list ten or more IHC markers, each with a positive or negative result, and no explanation of what any of them means. Vimentin and desmin are two of the most common. They are not the diagnosis — they are part of the evidence the pathologist uses to reach one.

Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026

  • Each marker has a specific role — Vimentin and desmin confirm different aspects of a tumour's origin. Positive for one does not mean positive for both, and neither alone makes the diagnosis.
  • No single marker is enough — Sarcoma subtypes are identified from the pattern across several markers. A positive for one means little without the rest of the panel.
  • A long panel is not a bad sign — Sarcomas require more markers than most cancers to classify correctly. More markers means more information for the pathologist, not more disease.
  • The pattern decides, not any single line — Your oncologist and pathologist read the combination of positive and negative results together before naming a subtype.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Talk to a medical oncologist

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Vimentin and desmin are structural proteins used as IHC markers to identify the tissue a soft tissue tumour comes from. Vimentin marks mesenchymal cells broadly; desmin marks muscle cells specifically. No single marker confirms a sarcoma subtype — the diagnosis comes from the pattern of several markers taken together.

What does each marker on a sarcoma IHC report mean?

Vimentin
A structural protein found in mesenchymal cells — cells that form connective tissue, fat, muscle, bone and cartilage. Nearly all sarcomas are vimentin-positive, but so are many carcinomas. A positive result tells the pathologist the tumour has mesenchymal characteristics. It is the starting point of the investigation, not the conclusion.
Desmin
A protein found in muscle cells, both smooth muscle and skeletal muscle. Positive desmin points toward muscle differentiation. It is typically positive in rhabdomyosarcoma, which arises from skeletal muscle, and in leiomyosarcoma, which arises from smooth muscle. A negative result moves the diagnosis away from muscle-type subtypes.
SMA (Smooth Muscle Actin)
Marks smooth muscle and myofibroblastic cells. Present in leiomyosarcoma and desmoid-type fibromatosis, among others. Because normal blood vessel walls also express SMA, it is always interpreted alongside desmin and other markers rather than read in isolation.
S100
Associated with neural crest-derived cells, including nerve cells and fat cells. Positive in nerve sheath tumours and in some tumours with fat-cell differentiation. Also positive in melanoma, which is why S100 is always read together with other markers to narrow the list.
MyoD1 and Myogenin
Proteins that drive skeletal muscle development. Their presence in a tumour is a strong indicator of rhabdomyosarcoma. Myogenin is the more specific of the two and is commonly used to confirm the diagnosis when other markers suggest skeletal muscle origin.
DOG1 and CD34
DOG1 is highly specific for gastrointestinal stromal tumour (GIST) and is used together with KIT. CD34 marks blood vessel cells and certain stromal tumours, including solitary fibrous tumour. Both appear on panels for tumours arising in or near the gut wall or body cavities.

Why does a sarcoma report have so many markers on it?

Sarcomas arise from many different connective tissue types, and the WHO classification recognises more than 70 distinct subtypes — many of which look almost identical under a microscope. No single marker separates them, so the pathologist builds a panel that eliminates possibilities one by one.

Which markers are absent matters as much as which are present. The final diagnosis comes from the pattern of positives and negatives across the whole panel, read together rather than line by line.

For some subtypes, even a complete IHC panel is not enough. Molecular testing — looking for specific gene rearrangements — is also needed before a final diagnosis can be confirmed. A longer report reflects careful, thorough work.

Not sure what this means for you?

Share your reports and a senior oncologist will explain your options in plain language — no obligation to start treatment.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What to look for when you receive the IHC report

  • Check whether a final diagnosis is stated, or whether the report lists a differential that still needs further testing.
  • Ask if any markers are still pending — the final interpretation may wait for one more result.
  • Find out whether molecular or genetic testing has also been requested alongside the IHC panel.
  • Ask your oncologist which markers were most important for this diagnosis, and why.
  • If the pathologist recommends review at a specialist sarcoma centre, take that up — this is standard guidance, not a sign of a problem.

Questions families ask about sarcoma IHC panels

What does a positive result on a marker actually mean?

A positive result means the protein being tested was detected in your tumour cells. The report also records how strongly it stained and in what proportion of cells — a strong, diffuse positive carries more weight than a weak or focal one. Your pathologist interprets the strength and distribution across all markers before reaching a conclusion. A single strong positive does not make a diagnosis on its own.

Does a negative result rule out a diagnosis?

Not always. A negative means the protein was not detected at a level the test can see — not that it is definitively absent. Sarcomas can be heterogeneous, meaning different areas of the tumour stain differently, so a small biopsy sample may not represent the whole. A single negative is rarely definitive on its own. Your pathologist weighs it against the rest of the panel and the clinical picture before drawing a conclusion.

Can IHC alone confirm a sarcoma diagnosis?

For some sarcoma subtypes, a well-chosen IHC panel is sufficient. For others — including Ewing sarcoma and synovial sarcoma — IHC points the direction but molecular confirmation is also required. Molecular testing looks for specific gene rearrangements that are characteristic of the subtype and cannot be detected by antibody staining alone. Your pathologist will request molecular testing when it is needed before issuing a final diagnosis.

Why does my report say 'consistent with' instead of 'confirms'?

Pathology reports use precise language by convention. 'Consistent with' means the pattern fits the diagnosis but other possibilities have not been fully excluded — often because molecular testing is still pending, or the biopsy was small. It does not mean the pathologist is uncertain about your case; it means they are being accurate about what the evidence shows at that stage. The language in the final report usually becomes more definitive once all tests are in.

Should we ask for a second opinion on the pathology?

ESMO and NCCN guidance both recommend that sarcoma pathology be reviewed at a specialised centre with a high caseload in soft tissue tumours. This is standard advice for all sarcomas, not a sign that anything was done incorrectly. Specialised pathologists see these panels routinely and may refine or occasionally revise the diagnosis. Ask your oncologist whether the slides have already been reviewed at a sarcoma centre, or whether a referral should be arranged before treatment planning begins.

Did you know?

The WHO Classification of Tumours of Soft Tissue and Bone recognises more than 70 distinct histological subtypes of soft tissue sarcoma.

Each has a different molecular profile, a different clinical behaviour, and in many cases a different approach to treatment — which is why a sarcoma IHC panel carries far more markers than a report for most other cancer types.

Source: WHO Classification of Tumours of Soft Tissue and Bone, 5th edition, 2020

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Does a vimentin-positive result mean I have a sarcoma?

Not on its own. Vimentin is expressed by nearly all sarcomas, but also by many carcinomas and some lymphomas. A positive result tells the pathologist that the tumour has mesenchymal characteristics and begins the investigation. The diagnosis depends on the complete panel, not on vimentin alone. Your oncologist will explain what the full pattern of results indicates for your specific case.

What does it mean if desmin is negative on my report?

A negative desmin result means the tumour does not show muscle differentiation at a level the test can detect. This narrows the list of possibilities — rhabdomyosarcoma and leiomyosarcoma are both typically desmin-positive, so a negative result makes those subtypes less likely. It does not mean there is no sarcoma. Your oncologist will explain which diagnosis the rest of the panel supports.

What does 'focal positivity' or 'weak staining' mean on a report?

These terms describe how strongly and in what proportion of cells the marker was detected. Strong and diffuse staining carries more weight than weak or focal staining, where only scattered cells show the marker at a low level. Whether focal positivity is significant depends on the specific marker and the clinical context. Your pathologist has already factored this into the overall interpretation — it is not something to read in isolation from the report.

My report lists markers I have never heard of. Does that mean something unusual is happening?

A long panel with unfamiliar markers usually means the pathologist is working through a differential diagnosis systematically, which is standard practice for soft tissue tumours. Because many sarcoma subtypes look similar under a microscope, the panel grows as possibilities are eliminated. Markers that look unusual compared with other cancer reports reflect the biology of soft tissue tumours, not a more alarming clinical situation.

Should I ask for a second opinion on the pathology report?

Yes, and you do not need a particular reason to ask. ESMO and NCCN both recommend that sarcoma pathology be reviewed at a specialist centre. Most oncologists treating sarcoma expect this and arrange it as part of standard care. A refined or revised diagnosis after review is not a sign of error in the first report — it reflects the genuine complexity of soft tissue tumour classification. Ask your oncologist whether this review has already been arranged.

When will the complete IHC report be ready?

Most IHC results are ready within a few working days of the biopsy being processed, though specialised markers and molecular tests take longer. If your report came back quickly with only a few markers, ask whether any results are still pending. Treatment planning is based on the final complete report, not preliminary results, so it is reasonable to ask your team for a timeline and confirmation of when all tests are expected back.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation